Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SNDX – Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.
SNDX
$9.98
Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $858,753,024.00
EPSttm : -3.85
finviz dynamic chart for SNDX
Syndax Pharmaceuticals, Inc.
$9.98
0.60%
$0.06

Float Short %

28.72

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

0.05

EPS Last/This Y

-0.05

EPS This/Next Y

1.1

Price

9.98

Target Price

32.67

Analyst Recom

1.23

Performance Q

-27.79

Relative Volume

0.77

Beta

0.73

Ticker: SNDX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04SNDX9.010.650.1331445
2025-07-07SNDX8.720.650.1731432
2025-07-08SNDX8.750.640.5131680
2025-07-09SNDX9.250.660.0634016
2025-07-10SNDX9.830.656.7534062
2025-07-11SNDX9.610.430.0330145
2025-07-14SNDX9.860.430.0030635
2025-07-15SNDX9.210.430.0530531
2025-07-16SNDX9.230.420.0130717
2025-07-17SNDX9.670.316.7428735
2025-07-18SNDX9.470.321.8828939
2025-07-21SNDX9.730.280.0021084
2025-07-22SNDX10.320.220.1525542
2025-07-23SNDX10.20.220.4526155
2025-07-24SNDX10.010.170.4726571
2025-07-25SNDX9.620.180.0126826
2025-07-28SNDX9.570.180.3126858
2025-07-29SNDX10.350.180.0327267
2025-07-30SNDX100.170.0029168
2025-07-31SNDX9.910.160.0030309
2025-08-01SNDX9.980.160.0530792
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04SNDX9.00-23.46.9-3.71
2025-07-07SNDX8.73-23.435.3-3.71
2025-07-08SNDX8.75-23.44.4-3.71
2025-07-09SNDX9.24-23.4-47.4-3.71
2025-07-10SNDX9.82-23.4-48.8-3.71
2025-07-11SNDX9.59-23.4-25.8-3.71
2025-07-14SNDX9.85-23.4-15.7-3.71
2025-07-15SNDX9.21-23.458.5-3.71
2025-07-16SNDX9.24-23.44.2-3.71
2025-07-17SNDX9.67-23.4-33.2-3.71
2025-07-18SNDX9.45-23.424.1-3.71
2025-07-21SNDX9.74-23.4-19.2-3.71
2025-07-22SNDX10.32-23.4-42.9-3.71
2025-07-23SNDX10.22-23.412.5-3.71
2025-07-24SNDX9.99-23.423.2-3.71
2025-07-25SNDX9.63-23.434.4-3.77
2025-07-28SNDX9.55-24.413.8-3.77
2025-07-29SNDX10.35-24.4-61.4-3.77
2025-07-30SNDX9.99-24.431.6-3.77
2025-07-31SNDX9.92-24.411.9-3.77
2025-08-01SNDX9.98-24.41.7-3.77
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04SNDX-0.083.3726.68
2025-07-07SNDX-0.083.3626.68
2025-07-08SNDX-0.083.3626.68
2025-07-09SNDX-0.083.3626.68
2025-07-10SNDX-0.083.3626.68
2025-07-11SNDX-0.083.3628.94
2025-07-14SNDX-0.083.4828.94
2025-07-15SNDX-0.083.4828.94
2025-07-16SNDX-0.083.4828.94
2025-07-17SNDX-0.083.4828.94
2025-07-18SNDX-0.083.4828.94
2025-07-21SNDX-0.323.4728.94
2025-07-22SNDX-0.323.4728.94
2025-07-23SNDX-0.323.4728.94
2025-07-24SNDX-0.323.4728.94
2025-07-25SNDX-0.323.4728.73
2025-07-28SNDX-0.323.2228.72
2025-07-29SNDX-0.323.2228.72
2025-07-30SNDX-0.323.2228.72
2025-07-31SNDX-0.323.2228.72
2025-08-01SNDX-0.323.2228.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.98

Avg. EPS Est. Current Quarter

-0.99

Avg. EPS Est. Next Quarter

-0.93

Insider Transactions

-0.32

Institutional Transactions

3.22

Beta

0.73

Average Sales Estimate Current Quarter

27

Average Sales Estimate Next Quarter

33

Fair Value

Quality Score

42

Growth Score

45

Sentiment Score

28

Actual DrawDown %

66.6

Max Drawdown 5-Year %

-69.9

Target Price

32.67

P/E

Forward P/E

PEG

P/S

19.64

P/B

3.99

P/Free Cash Flow

EPS

-3.87

Average EPS Est. Cur. Y​

-3.77

EPS Next Y. (Est.)

-2.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-757.52

Relative Volume

0.77

Return on Equity vs Sector %

-177.7

Return on Equity vs Industry %

-159.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

1.7
Syndax Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading